NICE U-turn means patients maintain access to Takeda's Adcetris

28 April 2017
2019_biotech_test_vial_discovery_big

The UK subsidiary of Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502), has been successful in maintaining ongoing access to Adcetris (brentuximab vedotin) on the National Health Service, with positive decisions from the National Institute for Health and Care Excellence (NICE) in two out of the three R/R Hodgkin lymphoma patient populations assessed.

This decision follows hard work, flexibility and determination from Takeda, supported by the clinical and patient community, in response to two previous draft negative recommendations from the NICE, said Takeda UK. The final guidance from the NICE will ensure that access is maintained to a vital standard of care treatment for adults with R/R CD30+ve Hodgkin lymphoma in England, Wales and Northern Ireland.

Within the final appraisal determination (FAD), the NICE has approved long-term funding for brentuximab vedotin for the treatment of adult patients with CD30+ve R/R Hodgkin lymphoma following an autologous stem cell transplant (ASCT). This means that clinicians will have guaranteed long-term access to brentuximab vedotin for this patient population via baseline commissioning. This recommendation is reliant on the company providing brentuximab vedotin at the price agreed with NHS England in the commercial access agreement.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology